Posts

Anki Malmborg Hager

SenzaGen invited to prestigious meeting at ICCVAM, US

Today, Tuesday the 27 September SenzaGen is invited to participate at a science Committee Meeting of the American organization ICCVAM *, which promotes the development of alternative methods to replace animal testing. Together with its US partner, Burleson Research Technologies, Inc., SenzaGen will participate in the official program and make a statement about Skin Sensitization Testing, the importance of secure and robust tests for classification of chemical substances with the ability to identify the potential of a substance causing allergy.

US ICCVAM is a permanent committee consisting of representatives from 15 federal regulatory and research agencies that requires, uses, generates, or disseminates toxicological and safety testing information to replace animal experiments. ICCVAM take expert advice from SACATM **, whose members include stakeholders from regulated industries, animal welfare organizations, academia, U.S. state or international regulatory bodies, and companies or organizations that develop, market or use test methods.

In connection with the SACATM meeting SenzaGen was invited together with their partner Burleson Research Technologies to make a statement in the session for Skin Sensitization Testing.

“It is a great achievement for us that we now have the opportunity, together with our partner Burleson Research Technologies, to give our views on the future development of testing in the U.S and to present GARD, before members of the prestigious SACATM. This shows that GARD is already on their radar, as the next-generation of sensitization testing. Only by cooperating at the highest level can we set a new industry standard for allergy testing in the US market, says Anki Malmborg Hager,” CEO of SenzaGen.

The ICCVAM meeting is being held in Research Triangle Park, North Carolina on Tuesday, 27 September and the CEO of SenzaGen AB, Anki Malmborg Hager will make her statement and give the recommendations in the session ICCVAM Roadmap to Skin Sensitization Testing at 11.25 am (EDT).

* ICCVAM: The Interagency Coordinating Committee on the Validation of Alternative Methods
** SACATM: Scientific Advisory Committee on Alternative Toxicological Methods

For more information:
Anki Malmborg Hager, CEO, SenzaGen AB
Mail: amh@senzagen.com
Phone: +46 768 284822

 

About GARD
By analyzing 200 and 389 markers, depending on the test, GARD generates massive amounts of data and delivers results with 90 % prediction accuracy. This can be compared to the gold standard, animal tests in mice, that provides 72 % prediction. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance is an allergen.

About SenzaGen
SenzaGen provides dermal and respiratory in vitro testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company’s unique test, GARD, is based on research from the Department of Immunotechnology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

SenzaGen Invited to High-Tech Health Research Expo in Washington, D.C.

SenzaGen have been invited by U.S. Representative Tom Marino to present the company’s technology at the High-Tech Health Research Expo in Washington, D.C., where SenzaGen will meet US congressmen and federal procurement officials interested in the use of high-tech human-focused methods to replace animal tests. The Expo takes place on September 15th, 2016.

The High-Tech Health Research Expo is organized by U.S. Representative Tom Marino who has been an outspoken leader for increased investments in this sector of the healthcare industry. The market for alternative and animal-free test methods is growing rapidly and there is a great interest for its benefits – scientifically and economically as well as from a public health perspective.

“The provisions to reduce animal testing under the reformed Toxic Substances Control Act (TSCA) will ensure an even bigger interest in the field and SenzaGen has a natural fit in this with its test being validated for the international market by OECD says Brian Rogers,” CEO of SenzaGen Inc.

At the Expo, selected companies will have the opportunity to present their technologies to Members of congress, congressional staffers and other representatives from different government agencies.  The goal of the Expo is to help advance this sector of the healthcare industry by creating an opportunity for the best and the brightest in the field to efficiently reach the largest number of decision-makers at once.

“We are very proud to participate. Now, our US subsidiary will have the opportunity to reach out to some of the most influential members of Congress, who really have a say in our industry. We see it as a confirmation of our US investment and our unique test method GARD says Anki Malmborg-Hager,” CEO of SenzaGen Sweden.

High-Tech Health Care Expo takes place at the Cannon House Office Building in Washington, DC on September 15, 2016. SenzaGen will participate with their U.S:  employees, and will have a stand where the company will demonstrate the latest technique to replace animal testing when performing allergy testing of chemicals and chemical ingredients.

 

For more information:

Anki Malmborg Hager, CEO
amh@senzagen.com
SE: +46 768 284822

Brian Rogers, Ph D, CEO US
brian.rogers@senzagen.com
US: +1 530 304 7648, +1 530 867 5600

 

About SenzaGen
SenzaGen provides in vitro dermal and respiratory testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company’s unique test GARD is based on research from the Department of Immunotechnology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

About GARD
By analyzing 200 and 389 genomic markers, depending on the test, instead of 1-2 markers as competing methods, GARD delivers results with 90 % accuracy. This can be compared to the golden standard, animal tests on mice that provide 72 % accuracy. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance cause allergy.

SenzaGen wins DI’s Gasellsprånget – most promising company to become Supergasell within 5 years

On May 25, SenzaGen was elected winner at the Swedish newspaper Dagens Industri’s event and competition Gasellsprånget, at the national finale in Gothenburg. After a tough round of questions and an audience poll, SenzaGen was elected winner with the greatest market potential and future outlook, leaving the competitor DigiExam a close second.

“SenzaGen has great future potential in a new and growing global market. We have been working very hard which makes it particularly rewarding to receive this award and the attention it creates. We are seeing an increased interest in our technology and I am confident that this award will lead to more exciting business opportunities in Europe and globally, says Anki Malmborg Hager”, CEO of SenzaGen.

About Gasellsprånget
Gasellsprånget is a competition highlighting Swedish growth companies on the rise. The competition is hosted by the Swedish newspaper Dagens Industri and is split into several regional competitions, from which two contestants are chosen to participate in the national finale.

“In the selection of finalists for Gasellsprånget 2016, the jury nominated the companies that have the best opportunities to become Supergasell within a 5-year period, based on analysis and on-stage presentations by the competing companies.”

 

For more information:
Anki Malmborg Hager, CEO, SenzaGen AB
E-mail: amh@senzagen.com
Phone: +46 768 284822

 

About SenzaGen
SenzaGen provides in vitro dermal and respiratory testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company’s unique test GARD is based on research from the Department of Immunotechnology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

 

About GARD
By analysing 200 and 389 genomic markers, depending on the test, instead of 1-2 markers as competing methods, GARD delivers results with 90 % accuracy. This can be compared to the golden standard, animal tests on mice, that provide 72 % accuracy. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance cause allergy.

SenzaGen elected winner at Gasellsprånget in Malmö

After a thrilling presentation and questioning round, SenzaGen was elected the winner at the local edition of Gasellsprånget in Malmö, Sweden. SenzaGen now has the opportunity to win Gasellsprånget on a national level at the finale in Gothenburg, on May 25

On May 11, the Swedish newspaper Dagens Industri hosted the local edition of Gasellsprånget in Malmö, Sweden. A competition which names the fastest growing companies in Sweden. The event was hosted at Clarion Hotel & Congress Malmö Live where participants got the opportunity to listen to presentations about entrepreneurship and development in the region, as well as mingle and network. SenzaGen was one of two companies who, during the evening, had the opportunity to present their company to the audience and a panel experts. After a round of questions from the experts, the audience voted and announced SenzaGen as the winner of Gasellsprånget Malmö.
“This feels like a great win and shows that there are many who believe in us, our business model and the team that we have put together to take the company forward. This event was a very good and exciting environment to pitch in, with many interesting questions from the panel of experts. I am delighted and overwhelmed by all who voted for us, says Anki Malmborg Hager”, CEO of SenzaGen.

Two finalists, selected by a jury, will now move forward and get to compete in the national finale at Gasellträffen in Gothenburg, on May 25. Based on the jury’s deliberation, analysis of the companies and an on-stage company presentation, the jury will select the finalist with the best opportunity to become a Supergasell within a 5-year-period.

 

For more information:
Anki Malmborg Hager, CEO, SenzaGen AB
E-mail: amh@senzagen.com
Phone: +46 768 284822

blue senzagen logo

Potency potential of chemicals using GARD shown by independent laboratory

The platform that forms the basis for the GARD sensitization assay, has been shown to have the potential to be an accurate tool for measuring the potency of sensitizing chemicals. The study was performed by an independent research group at Department of Immunotechnology, Lund University in Sweden and presented at the Society of Toxicology 55th Annual Meeting in New Orleans, 2016.

The new data were presented on Tuesday at the Society of Toxicology 55th Annual Meeting in New Orleans, poster session “Alternative Models for Ocular and Skin Toxicity”, abstract number 2205, P136.

“We have for a long time seen indications that this platform could predict potency and we are very happy to be able to present data that further points in that direction now, since it opens up completely new possibilities in skin sensitizations”, says Assoc. Prof. Malin Lindstedt, heading the group at Department of Immunotechnology.

Based at Medicon Village in Lund, SenzaGen develops and implements animal-free tests on chemicals and proteins for classification of sensitizers, primarily for the cosmetics and pharmaceutical industries. SenzaGen’s test GARD (Genomic Allergen Rapid Detection) measures significantly more parameters than existing tests on the market and has previously shown to deliver the most accurate prediction for hazard classification of chemicals. Now it has also shown potential to be a key player in the important field of risk assessment of chemicals by being able to predict the potency of chemicals.

“Potency has been the long-sought for application of sensitization tests. In risk assessment it is imperative to be able to predict not only the hazard of a chemical but more importantly how strong inducer of sensitization it is, i.e. the potency of the chemical. Lund University has now in a large study shown that GARD has this ability, which makes GARD unique, and we are looking forward to take part of this and develop it further”, says Anki Malmborg Hager, CEO of SenzaGen AB.

 

For more information:

Anki Malmborg Hager, CEO, SenzaGen AB
E-mail: amh@senzagen.com
Phone: +46 768 284822

Brian Rogers, CEO, SenzaGen Inc
E-mail: brian.rogers@senzagen.com
Phone: +1 530 304 7648

 

About GARD
By analyzing 200 and 389 markers, depending on the test, GARD generates massive amounts of data and delivers results with 90 % prediction accuracy. This can be compared to the golden standard, animal tests on mice, that provides 72 % prediction. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance is an allergen.

About SenzaGen
SenzaGen provides dermal and respiratory in vitro testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company’s unique test GARD is based on research from the Department of Immune Technology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

senzagen

SenzaGen is presenting at a hosted session at Society of Toxicology 55th Annual Meeting in New Orleans March 15, 2016

SenzaGen Senior Scientist, Dr. Henrik Johansson will give a presentation at an exhibitor hosted session at the Society of Toxicology 55th Annual Meeting in New Orleans, 15th of March.

The meeting promises more than 150 scientific sessions, approximately 350 ToxExpo exhibitors offering you the latest information on services and technology, thousands of abstract presentations, continuing education courses, awards presentations, receptions, career guidance and support, and more.

The topic for Dr. Johansson’s presentation
Genomics—The Future of Sensitization Testing and Safety Assessment is:
In vitro testing in human cellines using genomic technology is the future in safety testing of chemicals and proteins. SenzaGen is presenting their use of genomics for sensitization testing with GARD assays for skin and respiratory sensitization. Using +200 biomarkers enables better predictions, including potency information.

This session is an Exhibitor-Hosted Session. Although not an official part of the SOT Annual Meeting scientific program, its presentation is permitted by the Society.

The presentation will cover
– Accurate and convenient safety assessment of chemical sensitizers using GARD, an in vitro assay based on genomic biomarker signatures
– How genomic readouts can help facilitate simple models that effectively monitors a complex reality
– Versatile test systems allowing for a broad applicability domain

Attendees are welcomed from researcher community, industry, manufacturers, regulatory agencies, consultants, CROs and every one interested in safety testing of chemical compounds.

Details:
Genomics—The Future of Sensitization Testing and Safety Assessment
Exhibition hall, Room 211
Tuesday, March 15, 1:30 PM to 2:30 PM